[Behavior of human plasmin inhibitors in intravascularly increased fibrinolytic activity].
D000787:Angina Pectoris / Q000097:blood; D000991:Antithrombins / Q000032:analysis; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000188:drug therapy; D006348:Cardiac Surgical Procedures; D005112:Extracorporeal Circulation; D005341:Fibrinolysin / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006330:Heart Defects, Congenital / Q000601:surgery; D006801:Humans; D005779:Immunodiffusion; D007122:Immunoelectrophoresis; D008103:Liver Cirrhosis / Q000097:blood; D008259:Macroglobulins / Q000032:analysis; D009203:Myocardial Infarction / Q000097:blood; D009362:Neoplasm Metastasis / Q000097:blood; D010447:Peptide Hydrolases / Q000097:blood; D013300:Streptokinase / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000097:blood; D013927:Thrombosis / Q000097:blood; D014361:Trypsin Inhibitors
D000991:Antithrombins; D005343:Fibrinolytic Agents; D008259:Macroglobulins; D014361:Trypsin Inhibitors; D010447:Peptide Hydrolases; D013300:Streptokinase; D005341:Fibrinolysin
Verhalten menschlicher Plasmininhibitoren bei intravasal erhöhter fibrinolytischer Aktivität.